TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in memory satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bronchoalveolar lavage fluid interleukin 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy on tests of episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Task-related functional connectivity among posterior medial brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical benefit in solid tumor subgroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in limb muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Completion rate of rapid diagnostic processes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Geometric Mean Titer (GMT) of Serum Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reaching Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with Solicited Local and Systemic Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Gynaecological follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound imaging of wrists
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of moderate-to-severe diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to nutritional recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with an immunological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Leg Lateral Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seated Rotation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory cell profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactivation Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Children's Yale Brown-Obsessive Compulsive Scale for Autism Spectrum Disorder (CYBOCS-ASD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glutamatergic neurometabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow measurement using Laser speckle contrast imaging technique (LSCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic examination for diabetic foot exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects with distant metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pre-malignant progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Easier to apply Gradusox stockings compared to Sigvaris
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Easier to remove Gradusox stockings compared to Sigvaris
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Comfort level of Gradusox stockings compared to Sigvaris
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CRC recurrence or sign of lymph nodes or distant metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the activity of the anterior cingulate cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin incision time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent change in total abscess and inflammatory nodule count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of SCRI-CAR19v3 Manufacturing Success
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Radiographic fusion success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants reporting serious adverse events (SAEs) after single ascending doses
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting non-serious AEs after single ascending doses
Endpoint domain: Adverse events/effects
Primary endpoint: Deep molecular response (DMR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Free Remission (TFR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of classical CVD risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of coronary arteries with new thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of maternal circulating BH4 biomarkers levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of maternal nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn-around time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: infection-related morbidity episodes, parent-reported
Endpoint domain: Adverse events/effects
Primary endpoint: gluteus maximum muscle activity measured by Electromyography (EMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BMI in kg/m^2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity (AUROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale (HDRS-24)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Borg score index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PSQI index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Generation of aerosol particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in signal intensity of exhaled metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Perception of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful left common ostium isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under The Concentration-time Curve From Time Zero To Infinity (AUCinf) For Single-dose ALXN2050
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) For Single-dose ALXN2050
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Maximum Plasma Concentration (Tmax) For Single-dose ALXN2050
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Concentration-time Curve From Time Zero To The 12-hour Time Point (AUC0-12) For Multiple-dose ALXN2050
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Video quality of remote self-performed ultrasound exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak anterior deceleration of the sternum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants in need of emergency department visits caused by suicidal behavior
Endpoint domain: Adverse events/effects
Primary endpoint: CO2 diffusion through skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedation depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pan-Ig antibody response (pan-Ig anti-S1-RBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in anti-Nucleocapsid (N) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in SARS-CoV-2-binding antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with newly PCR-confirmed symptomatic COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with severe COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of change in mean blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: functional scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiological scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Mediterranean Diet (aMed) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nueromuscular Junction (NMJ) transmission instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cannabis use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of functional outcome (Harris Hip Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: proportion of activated monocyte cells (CD14+CD16+ phenotype)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thickness of Coracohumeral Ligament (CHL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Coracohumeral Distance (CHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Long Head of Biceps Tendon (LHBT) Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of hidden hypercortisolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of diabetes mellitus following acute pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline House-Brackmann
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Cytokine Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of individuals taking up the offer of an abdominal CT scan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma Asparaginase Activity (PAA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nadir Plasma Asparaginase Activity (NPAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in proteome levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in phosphoproteome levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in lipidome levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in epigenome levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in transcriptome levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Functional Device Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of major liver graft-related adverse events (LGRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Weight of older people
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-mental State Examination (MMSE) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Energy (kcal) ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monetary value of order
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Likelihood of using a bulk-buy promotion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Likelihood of selecting a larger or smaller size
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of greater than grade 3 adverse events leading to treatment cessation
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of VLX-1005
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of argatroban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of VLX-1005
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of argatroban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(inf) of VLX-1005
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(inf) of argatroban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who consent to each arm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Concentration Time Curve (AUC) from Time Zero to Infinity (AUCinf) of Darigabat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Darigabat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase Half-life (t½) of Darigabat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Typical weekly alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Use Consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cerebral concentrations of GABA and glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: accuracy of intraoral scanning techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative reintervention rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Long term effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of KYV-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of KYV-101
Endpoint domain: Adverse events/effects
Primary endpoint: Grip dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain conceptualization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Procedural Sedation required
Endpoint domain: Adverse events/effects
Primary endpoint: readmission due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Time required for complete dissolution of urate deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ascitic fluid analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascitic Fluid calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall perception of anxiety, modesty, privacy, and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity in Psoriatic arthritis (DAPSA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale (rest, movement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the alveolar crest height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the alveolar crest width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social anxiety measured by Liebowitz Social Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Molecular disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume reduction of Warthin's tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Need for invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: recurrence rate of AP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of different etiologies of liver cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Electrode array insertion success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence rate of OIPN
Endpoint domain: Adverse events/effects
Primary endpoint: trajectories of global cognitive efficiency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Academic Achievement Levels
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skill Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from device related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Functional patency of graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Two point discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: co2 Gap changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IVC collapsibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of bone marrow fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Inflammatory mediators; TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum amyloid-β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in maternal core body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women with hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonate status as determined by APGAR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonate status as determined by Umbilical Artery PH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Coagulopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Appendicular skeletal muscle mass index at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline handgrip strength at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline performance on the 5-repetition sit-to-stand test at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline performance on 6-metre walk test at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limited Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: SpO2 reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBR at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal Parasiticidal Concentration (MPC90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parasite Reduction Rate in 48 h (log10PRR48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Activity Measure for Post Acute Care (AMPAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frailty Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-albumin levels at fasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean pain interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean Patient Activation Measure (PAM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Clinically Significant Change in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Change in Physical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes